Edition:
United Kingdom

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

14.58USD
18 Jan 2019
Change (% chg)

-- (--)
Prev Close
$14.58
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
238,037
52-wk High
$29.07
52-wk Low
$11.00

Latest Key Developments (Source: Significant Developments)

Flexion Therapeutics Enrolls First Patient In Phase 3 Trial Of Zilretta In OA Of The Hip
Wednesday, 2 Jan 2019 

Jan 2 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 3 TRIAL OF ZILRETTA® (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN OA OF THE HIP AND REPORTS RESULTS FROM SHIP STUDY.FLEXION THERAPEUTICS INC - PHASE 3 HIP OA REGISTRATION TRIAL EXPECTED TO COMPLETE IN 2020.FLEXION THERAPEUTICS - ADDITIONAL PHASE 2 STUDIES OF SHOULDER OA AND ADHESIVE CAPSULITIS (FROZEN SHOULDER) PLANNED FOR H2 2019.FLEXION-POSITIVE RESULTS FROM PHASE 2 PHARMACOKINETICS STUDY OF ZILRETTA IN OA OF SHOULDER, HIP SHOWED PROFILES CONSISTENT WITH OLDER STUDIES IN KNEE.FLEXION THERAPEUTICS INC - PHASE 2 RESULTS DEMONSTRATED THAT ZILRETTA WAS GENERALLY SAFE AND WELL TOLERATED.  Full Article

Flexion Therapeutics Reports Q2 Loss Per Share Of $1.16
Tuesday, 7 Aug 2018 

Aug 7 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS REPORTS SECOND-QUARTER 2018 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS.Q2 SALES $3.8 MILLION VERSUS I/B/E/S VIEW $4.3 MILLION.QTRLY LOSS PER SHARE $1.16.QTRLY REVENUE $3.8 MILLION.Q2 EARNINGS PER SHARE VIEW $-1.23, REVENUE VIEW $4.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Flexion Therapeutics Acquires Rights To Genequine Biotherapeutics' Non-Opioid Drug
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - Flexion Therapeutics Inc ::FLEXION THERAPEUTICS ANNOUNCES ACQUISITION OF NOVEL, NON-OPIOID ASSET FOR OSTEOARTHRITIS OF THE KNEE.FLEXION THERAPEUTICS INC - ENTERED INTO A DEFINITIVE AGREEMENT WITH GENEQUINE BIOTHERAPEUTICS GMBH TO ACQUIRE GLOBAL RIGHTS TO GQ-20.FLEXION THERAPEUTICS - CO OBTAINED EXCLUSIVE LICENSE TO UNDERLYING INTELLECTUAL PROPERTY RIGHTS FOR HUMAN USE OF GQ-203 FROM BAYLOR COLLEGE OF MEDICINE.FLEXION THERAPEUTICS - CO TO MAKE UPFRONT PAYMENT OF $2 MILLION TO GENEQUINE & MAY INCUR MILESTONE PAYMENTS OF UP TO $8.7 MILLION THROUGH PHASE 2 POC.  Full Article

Flexion therapeutics reports third-quarter results
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights.Flexion Therapeutics Inc - qtrly basic and diluted net loss per share $1.07‍​.  Full Article

Flexion Therapeutics announces pricing of public offering of common stock
Wednesday, 11 Oct 2017 

Oct 11 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces pricing of public offering of common stock.Says public offering of 4.80 million common shares priced at $25.50per share.  Full Article

Flexion Therapeutics- Proposed public offering of 4 mln common shares
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces proposed public offering of common stock.Says offering 4.00 million common shares.Flexion Therapeutics Inc - Flexion intends to use net proceeds from offering to fund manufacturing and commercialization of Zilretta(TM)​.  Full Article

Flexion Therapeutics announces FDA approval of Zilretta for osteoarthritis knee pain
Friday, 6 Oct 2017 

Oct 6 (Reuters) - Flexion Therapeutics Inc :Flexion Therapeutics announces FDA approval of Zilretta (triamcinolone acetonide extended-release injectable suspension) for osteoarthritis (OA) knee pain.Says ‍product label also includes positive data from type 2 diabetes study​.Says ‍commercial supply expected to be available by late October following recent completion of manufacturing process validation​.  Full Article